Follicular lymphoma (FL) is the most frequently occurring indolent non-Hodgkin lymphoma,
with generally favorable outcomes but a variable clinical course. Recent studies have …

For the majority of patients with newly diagnosed follicular lymphoma (FL), current
treatments, while not curative, allow for long remission durations. However, several …

PURPOSE Understanding the immunobiology of the 15% to 30% of patients with follicular
lymphoma (FL) who experience progression of disease within 24 months (POD24) remains …

Both total metabolic tumor volume (TMTV), computed on baseline positron emission
tomography (PET), and end of induction (EOI) PET are imaging biomarkers showing …

Follicular lymphoma (FL) is a generally incurable malignancy that evolves from
developmentally blocked germinal center (GC) B cells. To promote survival and immune …

Purpose: T cells infiltrating follicular lymphoma (FL) tumors are considered dysfunctional, yet
the optimal target for immune checkpoint blockade is unknown. Characterizing coinhibitory …

The treatment of patients with relapsed or refractory lymphoid neoplasms represents a
significant clinical challenge. Here, we identify the pro‐survival BCL‐2 protein family …

Purpose: This study was aimed at evaluating the feasibility, safety, immunologic and clinical
responses in patients with follicular lymphoma treated with monocyte-derived dendritic cells …

Reference atlases, molecular and spatial maps of mammalian tissues, are critical resources
for discovery efforts and translational research. Their utility is dependent on operationalizing …

Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most
patients achieve long-lasting remissions and have excellent overall survival (OS) with …